AngioJet(R) Therapy Shown Safe and Effective as Part of Rescue Percutaneous Coronary Interventions

Possis Medical, Inc. (NASDAQ:POSS), announced today the recentpublication of an important clinical study that included itsAngioJet(R) Rheolytic(TM) Thrombectomy Catheter System. The studyevaluated clinical outcomes in high-risk acute coronary syndrome (ACS)patients whose initial treatment with thrombolytic (clot-busting)drugs had failed, and who therefore required urgent, rescuepercutaneous catheter-based intervention (PCI).

The study was conducted by Dr. Ray Matthews and his colleagues atGood Samaritan Hospital and the UCLA Medical Center in Los Angeles. Itappears in the February 2006 issue of Catheterization andCardiovascular Interventions. Over 200 patients were included in thestudy; 21 percent of these received AngioJet treatment as part of therescue PCI. The authors concluded in part: "This observational,consecutive, real-world study of contemporary rescue PCI for failedthrombolysis shows a high use of coronary stents, Rheolyticthrombectomy, glycoprotein IIbIIIa inhibitors, and intraortic balloonpump placement. Angiographic and clinical success was high with lowbleeding complications and low in-hospital mortality . . .".

Robert G. Dutcher, President and CEO of Possis Medical, Inc., saidthe company is pleased with these results. "Clearly, the AiMI studyresults announced in 2004 are not the whole story. This independentstudy is just the latest in a growing series of real-world experiencesfrom leading operators showing that AngioJet thrombectomy is safe andeffective in PCI, including in high-risk and emergent patients."

Dutcher also noted that Dr. Matthews will participate in aroundtable discussion of AngioJet coronary thrombectomy by leadinginterventional cardiologists, hosted by Possis Medical, at the Marchannual meeting of the American College of Cardiology. "This roundtablediscussion will bring together many of the interventionalists whoseown growing thrombectomy experience illustrates the clinical benefitsof the AngioJet System for removing coronary thrombus. We are lookingforward to this discussion among experts at ACC, and it subsequentpublication, to further guide interventionalists toward maximizing thevalue of AngioJet coronary thrombectomy for their patients."

Continued Dutcher, "This panel discussion is part of ourcontinuing efforts to obtain, support, and publicize useful clinicalscience about AngioJet thrombectomy in coronary patients. Theaccelerating JETSTENT trial of AngioJet thrombectomy with PCI comparedto PCI alone in heart attack patients is another key element in theseefforts. We believe that these ongoing initiatives will prove anewthat AngioJet thrombectomy is an essential component in the coronaryinterventionalist's management of acute coronary disease."

Possis Medical, Inc. develops, manufactures and markets pioneeringmedical devices for the large and growing cardiovascular and vasculartreatment markets. The AngioJet(R) Rheolytic(TM) Thrombectomy Systemis marketed in the United States for blood clot removal from nativecoronary arteries, leg arteries, coronary bypass grafts and AVdialysis access grafts.

Certain statements in this press release constitute"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the SecuritiesExchange Act of 1934, as amended. These statements relate to clinicalstudy initiatives, are based on our current expectations andassumptions, and entail various risks and uncertainties that couldcause actual results to differ materially from those expressed in suchforward-looking statements. A discussion of these and other factorsthat could impact the Company's future results are set forth in thecautionary statements included in Exhibit 99 to the Company's Form10-K for the year ended July 31, 2005, filed with the Securities andExchange Commission.